Representation of blacks, women, and the very elderly (aged ≥80) in 28 major randomized clinical trials

Ethnicity and Disease

Volumn 9, Issue 3, 1999, Pages 333-340

  Hall, W Dallas ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ISHIB   (United States)

Author keywords

African Americans; Blacks; Clinical Trials; Diabetes Mellitus; Elderly; Recruitment; Women

Indexed keywords

AFRICAN AMERICAN; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MALE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; WOMEN;

EID: 0033182638     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research. Republished March 28, 1994. Publ No. 59 FR 14508.
2. Gurwitz JH, Col NR Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA. 1992;268:1417-1422.
3. Svensson CK. Representation of American blacks in clinical trials of new drugs. JAMA. 1989;261: 263-265.
4. Harris Y, Gorelick PB, Samuels P, Bempong I. Why African Americans may not be participating in clinical trials. J Natl Med Assoc. 1996;88:630-634.
5. Roberson NL. Clinical trial participation. Viewpoints from racial/ethnic groups. Cancer. 1994; 74(suppl 9):2687-2691.
6. Gavaghan H. Clinical trials face lack of minority group volunteers. Nature. 1995;373:178.
7. Hall WD. Screening and recruitment of elderly participants into large-scale cardiovascular research trials. In: Wenger NK, ed. Inclusion of Elderly Individuals in Clinical Trials. Kansas City, Mo: Marion Merrell Dow Inc; 1993:67-72.
8. Agodoa L. African-American Study of Kidney Disease and Hypertension (AASK) - clinical trial update. Ethn Dis. 1998;8:249-253.
9. Wright JT Jr. Department of Veterans Affairs National Meeting; May 26-28, 1999; Washington, DC.
10. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
11. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (AL-LHAT). J Hypertens. 1996;9:342-360.
12. Cushman WC, Black HR, Probstfield JL, Holland JJ, Margolis K, et al, for the ALLHAT group. Blood pressure control in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens. 1998;11(4, Pt 2): 17A. Abstract.
13. Wing LM, Reid CM, Ryan P, et al. Second Australian National Blood Pressure Study (ANBP2). Australian comparative outcome trial of ACE-inhibitor- and diuretic-based treatment of hypertension in the elderly. Clin Exp Hypertens. 1997;19: 779-791.
14. Reid CM, Wing LMH, for the ANBP2 Management Committee. Second Australian National Blood Pressure Study (ANBP2) progress report. Am J Hypertens. 1999;12(4, Pt 2):143A. Abstract.
15. Hansson L, Hedner T, Lindholm L, et al. The Captopril Prevention Project (CAPPP) in hypertension - baseline data and current status. Blood Press. 1997;6:365-367.
16. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
17. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
18. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
19. Black HR, Elliott WJ, Neaton JD, et al. Rationale and design for the controlled onset verapamil investigation of cardiovascular endpoints (CONVINCE) trial. Control Clin Trials. 1998;19:370-390.
20. Black HR, Elliott WJ, Neaton JD, et al, for the CONVINCE study group. Baseline characteristics of the 16,605 patients in the CONVINCE study. J Hypertens. 1999;17(suppl 3):S201. Abstract
21. DCCT Research Group. Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329: 977-986.
22. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
23. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of losartan (EXCEL) study results. Arch Intern Med. 1991;151:43-49.
24. Prisant LM, Downton M, Watkins LO, et al. Efficacy and tolerability of losartan in 459 African-Americans with hypercholesterolemia. Am J Cardiol. 1996;78:420-424.
25. Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
26. HDFP Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. II. Mortality by race-sex and age. JAMA. 1979;242:2572-2577.
27. Langford HG, Stamler J, Wassertheil-Smoller S, Prineas RJ. All-cause mortality in the Hypertension Detection and Follow-up Program: findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis. 1986;29 (suppl 1):29-54.
28. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351:1755-1762.
29. Personal verbal communication. Ken Jamerson, June 1999. (Number of blacks in HOT).
30. Dahlof B, Devereaux R, de Faire U, et al. The losartan intervention for endpoint reduction (LIFE) in hypertension study. Rationale, design, methods. Am J Hypertens. 1997;10:705-713.
31. Dahlof B, Devereaux RB, Kjeldsen SE, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan intervention for endpoint reduction in hypertension. Hypertension. 1998;32:989-997.
32. Kjeldsen SE, Dahlof B, Devereaux RB, et al. One year of antihypertensive treatment in patients with LVH in the LIFE study. Am J Hypertens. 1999;12 (4, Pt 2):142A. Abstract.
33. Kjeldsen SE, Dahlof B, Devereaux RB, et al, for the LIFE Study Group. One year of antihypertensive treatment in patients with LVH: the LIFE study. J Hypertens. 1999;17(suppl 3):S201. Abstract.
34. Klahr S, Levey A, Beck G, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877-884.
35. Hebert LA, Kusek JW, Green T, et al. Effects of blood pressure control on progressive renal disease in the Modification of Diet in Renal Disease study. Hypertension. 1997;30:428-435.
36. Grimm RH Jr, Cohen JD, Smith WM, Falvo-Gerard L, Neaton JD, et al. Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six-year intervention results for men in special intervention and usual care groups. Arch Intern Med. 1985;145:1191-1199.
37. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
38. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255-3264.
39. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996; 276:1886-1892.
40. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
41. Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Syst-China Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998;16:1823-1829.
42. Wang JG, Staessen JA, Gong L, Liu LS, for the Syst-China Trial Investigators. Subgroup analysis of the placebo-controlled Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med. In press.
43. Staessen JA, Fagard R, Thijs L, et al. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
44. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
45. TOMHS Research Group. The treatment of mild hypertension study. A randomized placebo-controlled trial of a nutritional-hygenic regimen along with various drug monotherapies. Arch Intern Med. 1991;151:1413-1423.
46. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998;279:839-846.
47. Personal written communication, Mark Espeland, June 1999. (Number of diabetics in TONE).
48. UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
49. UKPDS. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-720.
50. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-921.
51. Mann J, Julius S. The valsartan antihypertensive long-term use evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press. 1998;7:176-183.
52. Julius S, Brunner HR, Hansson L, et al. The VALUE trial: patient demographics and progress report. Am J Hypertens. 1999;12 (4, Pt 2):142A. Abstract.
53. Julius S, Brunner HR, Hansson L, et al. The VALUE trial: patient demographics and progress report. J Hypertens. 1999;17(suppl 3):S202. Abstract.
54. Lindholm LH, Hansson L, Dahlof B, et al. The Swedish trial in old patients with hypertension-2 (STOP-Hypertension-2): a progress report. Blood Press. 1996;5:300-304.
55. US Census Bureau. Census. Population Estimates Program, Population Division. Release date: June 4, 1999. www.census.gov/population, accessed 6/ 30/99.
56. WHI Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
57. Hall WD. Hypertension. In: Wenger NK, ed. Cardiovascular Disease: Recognition and Management in the Octogenarian and Beyond. London, England: Martin Dunitz Ltd; 1999:237-254.
58. Gueyffier F, Bulpitt C, Boissel J-P, et al. Antihypettensive drugs in very old people: a subgroup meta-analysis of randomised clinical trials. Lancet. 1999;353:793-796.
59. Bulpitt CJ, Fletcher AE, Amery A, et al. The hypertension in the very elderly trial (HYVET). Rationale, methodology and comparison with previous trials. Drugs Aging. 1994;5:171-183.
60. Beckett NS, Sadler JD, Fletcher AE, Bulpitt CJ, for the HYVET Pilot Study. The effects of diuretics and angiotensin converting enzyme inhibitors on renal function in the very elderly. Results from the HYVET pilot trial. J Hypertens. 1999; 17(suppl 3):S86. Abstract.